Table 1. Demographic and clinical characteristics of patients with TGCV investigated.
Patients (N=9) | |
Age of diagnosis | 58.6±11.1* |
Sex: Male/Female (n) | 6/3 |
Body mass index (kg/m2) | 19.1±5.5* |
Hemodialysis duration (days) | 5,244±4,249* |
Etiologies of end stage renal disease (n) | ADPKD (1), Nephrosclerosis (2), Diabetic nephropathy (3), FSGS (1), Unknown (2) |
Co-morbidities | |
Diabetes mellitus (n) | 4 |
Dyslipidemia (n) | 2 |
Hypertension (n) | 6 |
Hemoglobin (g/dL) | 11.4±1.3* |
Serum lipid levels (mg/dL) | |
Triglyceride | 111±47* |
Low-density lipoprotein-cholesterol | 72±25* |
High-density lipoprotein-cholesterol | 50±11 * |
Low LVEF (<40%) (n) | 2 |
Diffuse coronary atherosclerosis (n) | 7 |
Outcomes | |
Follow-up period from TGCV diagnosis (days) | 1,713±1,996* |
All-cause of death (n) | 4 |
Mean±standard deviation
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; FSGS, focal segmental glomerulosclerosis; LVEF, left ventricular ejection fraction; N, number; TGCV, triglyceride cardiomyovasculopathy